Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expected to report third quarter earnings results, before market open, on Friday 6th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.12 per share.
Looking ahead, the full year income are expected at $ 0.59 per share on the revenues of $ 1934.16 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,875.00 million ~ $ 1,975.00 million, where as bottomline are predicted in a range of $ 0.45 ~ $ 0.60 per share
Click Here For More Historical Outlooks Of Amneal Pharmaceuticals, Inc.
Previous Quarter Performance
Amneal Pharmaceuticals, Inc. reported income for the second quarter of $ 0.13 per share, from the revenue of $ 464.66 million. The quarterly earnings boosted 44.44 percent while revenues developed 14.83 percent compared with the same quarter last year.
Wall street analysts are predicting, AMRX to report 2Q20 income of $ 0.10 per share from revenue of $ 457.26 million. The bottom line results beat street analysts by $ 0.03 or 30.00 percent, at the same time, top line results outshined analysts by $ 7.40 million or 1.62 percent.
Stock Performance
Shares of Amneal Pharmaceuticals, Inc. traded up $ 0.13 or 2.71 percent on Thursday, reaching $ 4.93 with volume of 1.89 million shares. Amneal Pharmaceuticals, Inc. has traded high as $ 4.96 and has cracked $ 4.64 on the downward trend
According to the previous trading day, closing price of $ 4.93, representing a 100.00 % increase from the 52 week low of $ 2.40 and a 17.1 % decrease over the 52 week high of $ 5.79.
The company has a market capital of $ 727.37 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Recent Analyst recommendations
- On 9th October 2020, maintained by Piper Sandler at Overweight rating, with $ 6.00 target price.
Conference Call
Amneal Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.amneal.com
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
